Regulatory Sourcebook eBook
Read the article:
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Read the eBook:
BioPharm International October 2021 eBook
Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.
As the COVID-19 pandemic continues, one pressing concern for the industry is ensuring the supply of legitimate COVID-19 vaccines. It is estimated that 30.7% of people globally have received at least one dose of a COVID-19 vaccine, while 16% of the world population is fully vaccinated, according to Our World in Data (1). In a 2021 report from ResearchAndMarkets.com, three different potential scenarios for the future of COVID-19 vaccines were forecasted (2):
No matter the scenario, COVID-19 vaccines will be important in the coming years. Therefore, now more than ever, the supply chain needs to be secure to ensure the population can have access to legitimate vaccines. But substandard and falsified COVID-19 vaccines—commonly referred to as counterfeit vaccines—continue to be a threat globally.
Read the article:
The Real Danger of Substandard and Counterfeit COVID-19 Vaccines
Read the eBook:
BioPharm International October 2021 eBook
Meg Rivers is a senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
BioPharm International
eBook: October 2021
Pages: 6-9
When referring to this article, please cite it as M. Rivers, “The Real Danger of Substandard and Counterfeit COVID-19 Vaccines," BioPharm International eBook (October 2021).
almost 4 years ago
Industry Organizations Assist Pharma During the Pandemic and Beyondalmost 4 years ago
NIST Proposes Clarifications to Bayh-Dole March-in Rights Regulationsalmost 4 years ago
How Artificial Intelligence Impacts the Global Regulatory Environmentalmost 4 years ago
Selecting the Right CMC Strategy for Biologicsalmost 4 years ago
The Evolving Biosimilar Approachalmost 4 years ago
Serialization and Aggregation from a Manufacturing Perspectivealmost 4 years ago
Collecting Industry’s Thoughts on FDA FARS ReportStay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.